BNET Industries
Salix Pharmaceuticals Ltd. (SLXP) is in the Pharma Industry
- Revenue
- Dec 31 2007
- $235.7M
- Profit
- Dec 31 2007
- $8.2M
- Market Cap
- Nov 28 2008
- $389.3M
Latest News and Analysis
Salix Pharmaceuticals, Ltd. Q3 2008 Earnings Call Transcript
Question-and-Answer SessionOperator Thank you. At this time, we invite all listeners to ask questions. Operator instructions We will go first to Bert Hazlett with BMO Capital Markets. Bert Hazlett – BMO Capital Markets Thanks. Thanks for taking the question. Well, congratulations on the approval, first of all – of...
Salix Pharmaceuticals Ltd. Q2 2008 Earnings Call Transcript
Question-and-Answer SessionOperator Operator Instructions. We'll go first to Scott Hirsch with Credit Suisse. Scott Hirsch - Credit Suisse Yeah, hi, guys, a few questions for you. First of all, can you give us an update on the AG trial and any status going on with that? Carolyn Logan We...
Salix Pharmaceuticals Ltd. Q1 2008 Earnings Call Transcript
Question-and-Answer SessionOperator And, thank you. Operator Instructions. We will go to Michael Tong with Wachovia Capital. Michael Tong Hi good afternoon Carolyn and Adam. I have just a couple of quick questions. In your revenue guidance for the second quarter, do you incorporate a potentially initial stocking for Balsalazide...
Salix Pharmaceuticals Ltd. Q4 2007 Earnings Call Transcript
Question-and-Answer Session Operator Operator Instructions. Our first question today will come from [Scott Hirsch] with Credit Suisse. Scott Hirsch - Credit Suisse Yeah, hi there. Carolyn Logan All right. Scott Hirsch - Credit Suisse So a few questions for you; one, with respect to the guidance, how much inventory...
Salix Pharmaceuticals Q3 2007 Earnings Call Transcript
Question-and-Answer SessionOperator Operator Instructions And we will take our first question from Michael Tong with Wachovia Securities. Michael Tong - Wachovia Securities Hi. Good afternoon, Carolyn. Carolyn Logan Hi, Michael. Michael Tong - Wachovia Securities Just want to get a little bit better clarity on the, I guess the...
Salix Pharmaceuticals Reports 2Q2005 Results; Total Product Revenue Increases 81% Over 2Q04; Salix Delivers $0.13 EPS
RALEIGH, N.C. -- Salix Pharmaceuticals, Ltd. (NASDAQ: SLXP) today announced financial and operating results for the quarter ended June 30, 2005. Total product revenue was $35.1 million for the second quarter of 2005 compared to $19.4 million for the second quarter of 2004. This represents a year-over-year increase of...
Salix Pharmaceuticals Moves Forward with XIFAXAN Travelers' Diarrhea Prevention Study; First Step toward XIFAXAN Filing for Prophylactic Indication
RALEIGH, N.C. -- Salix Pharmaceuticals, Ltd. (NASDAQ:SLXP) announced today that it has begun enrolling and dosing subjects in a Phase III study to evaluate the efficacy and safety of XIFAXANTM rifaximin tablets 200 mg for the prevention of travelers' diarrhea TD. XIFAXANTM, a gut selective, non-systemic, virtually non-absorbed (less...
"Stocks on the Rise".
M2 PRESSWIRE-24 June 2005-WallStreetGrapevine: "Stocks on the Rise"C1994-2005 M2 COMMUNICATIONS LTD RDATE:24062005 Wall Street, NYC--Today, wallstreetgrapevine.com, named; Arete Industries Inc. (OTC BB: ARET), Cyberlux Corp. (OTC BB: CYBL), Inkine Pharmaceuticals Inc. (Nasdaq SC: INKP), and Industrial Services of America (Nasdaq...
Salix Pharmaceuticals to Present at William Blair & Company Conference
RALEIGH, N.C. -- Salix Pharmaceuticals, Ltd. (NASDAQ:SLXP) today announced that the Company will present at the William Blair & Company 25th Annual Growth Stock Conference in Chicago, IL on Wednesday, June 22 at 12:10 p.m. ET. Interested parties can access a live audio webcast of the presentation at http://www.salix.com....
Salix Pharmaceuticals to Present at Thomas Weisel Partners Conference
RALEIGH, N.C. -- Salix Pharmaceuticals, Ltd. (NASDAQ: SLXP) today announced that the Company will present at the 7th Annual Thomas Weisel Partners Growth Forum in San Francisco, CA on Tuesday, June 14 at 5:05 p.m. ET. Interested parties can access a live audio web cast of the presentation at...
Salix Pharmaceuticals to Present at UBS Global Pharmaceuticals Conference
RALEIGH, N.C. -- Salix Pharmaceuticals, Ltd. (NASDAQ: SLXP) today announced that the Company will present at UBS Global Pharmaceuticals Conference in New York, NY on Tuesday, May 24 at 3:00 p.m. ET. Interested parties can access a live audio web cast of the presentation at http://www.salix.com. A replay of...
Stocks on the Rise.
M2 PRESSWIRE-13 May 2005-WallStreetGrapevine: Stocks on the RiseC1994-2005 M2 COMMUNICATIONS LTD RDATE:13052005 Wall Street, NYC - Today, wallstreetgrapevine.com, named; Martin Nutraceuticals Inc. (Pink Sheets: MTNU), Orphan Medical Inc. (Nasdaq NM: ORPH), Bone Care International Inc. (Nasdaq NM: BCII), and Salix ...
Salix Pharmaceuticals to Present at Banc of America Health Care Conference
RALEIGH, N.C. -- Salix Pharmaceuticals, Ltd. (NASDAQ: SLXP) today announced that the Company will present at Banc of America Securities Heath Care Conference in Las Vegas, NV on Thursday, May 19 at 11:40 a.m. ET. Interested parties can access a live audio web cast of the presentation at http://www.salix.com....
Salix Pharmaceuticals Announces 1Q 2005 Financial Results Conference Call and Webcast
RALEIGH, N.C. -- Salix Pharmaceuticals, Ltd. (NASDAQ: SLXP) today announced that the Company will report first quarter ended March 31, 2005 financial results before the market opens on Wednesday, May 11, 2005. The Company will host a conference call at 9:00 a.m. ET, on Wednesday, May 11, 2005. Interested...
Salix Pharmaceuticals to Present at Rodman & Renshaw Global Healthcare Conference
RALEIGH, N.C. -- Salix Pharmaceuticals, Ltd. (NASDAQ: SLXP) today announced that the Company will present at the Rodman & Renshaw Techvest 2nd Annual Global Healthcare Conference in Paris, France on Wednesday, May 4 at 8:20 a.m. (2:20 a.m. ET.) Interested parties can access a live audio web cast of...
Salix Pharmaceuticals Reports XIFAXAN Clinical Update; Rifaximin -XIFAXAN- Studied in Five Investigator-Initiated Trials
RALEIGH, N.C. -- Salix Pharmaceuticals, Ltd. (NASDAQ: SLXP) today announced that results of five investigator-initiated trials of rifaximin will be presented at Digestive Disease Week 2005 DDW. Study investigators will present their findings during DDW 2005 which will be held May 14-19, 2005 in Chicago, IL. "There is a...
Salix Pharmaceuticals to Present at CIBC World Markets Conference
RALEIGH, N.C. -- Salix Pharmaceuticals, Ltd. (NASDAQ: SLXP) today announced that the Company will present at the CIBC World Markets Annual Biotechnology and Specialty Pharmaceutical Conference in New York, NY on Tuesday, April 5 at 3:45 p.m. ET. Interested parties can access a live audio web cast of the...
Salix Pharmaceuticals to Present at Suntrust Robinson Humphrey Conference
RALEIGH, N.C. -- Salix Pharmaceuticals, Ltd. (NASDAQ: SLXP) today announced that the Company will present at the SunTrust Robinson Humphrey's Therapeutics Conference in New York, NY on Tuesday, March 1, 2005 at 11:05 a.m. ET. Interested parties can access a live audio web cast of the presentation at http://www.salix.com....
Salix Pharmaceuticals to Present at NCINVEST Conference
RALEIGH, N.C. -- Salix Pharmaceuticals, Ltd. (NASDAQ: SLXP) today announced that the Company will present at NCINVEST 2005 in Chapel Hill, NC on Wednesday, February 16 at 11:00 a.m. ET. Interested parties can access a live audio web cast of the presentation at http://www.salix.com. A replay of the presentation...
Salix Pharmaceuticals Announces 2Q 2004 Financial Results Conference Call and Webcast
RALEIGH, N.C. -- Salix Pharmaceuticals, Ltd. (NASDAQ: SLXP) today announced that the company will report second quarter ended June 30, 2004 financial results before the market opens on Monday, August 9, 2004. The Company will host a conference call at 9:00 a.m. ET, on Monday, August 9, 2004. Interested...
- Next »
- page 1 of 2
- « Previous
Sort byClose
View by Content TypeClose
- Incorporated: 1993
- CEO: Ms. Carolyn J. Logan
Salix Pharmaceuticals is a pharmaceutical company that acquires, develops and markets prescription drugs for the treatment of gastrointestinal diseases, which are those affecting the digestive tract. At Dec 31 2007, Co.'s main products included: Colazal® (balsalazide disodium) capsules, Xifaxan® (rifaximin) tablets, and MoviPrep® (PEG 350, sodium sulfate, sodium chloride, potassium chloride, sodium ascorbate and ascorbic acid for oral solution), Azasan® azathioprine tablets; and its product candidates included: balsalazide disodium tablets, granulated mesalamine, vapreotide acetate and Metoclopramide-Zydis®. Co. markets its products to U.S. gastroenterologists via its direct sales force.
Key Competitors
Industry Transcripts by Seeking Alpha
-
Indevus Pharmaceuticals, Inc. F4Q08 (Qtr End 09/30/08) Earnings Call Transcript
on Nov 25, 2008about IDEV
-
Noven Pharmaceuticals, Inc. Q3 2008 Earnings Call Transcript
on Nov 24, 2008about NOVN
-
XenoPort, Inc. Q3 2008 Earnings Call Transcript
on Nov 24, 2008about XNPT
-
Repligen Corporation F2Q09 (Qtr End 09/30/08) Earnings Call Transcript
on Nov 24, 2008about RGEN
-
Omrix Biopharmaceuticals, Inc. Q3 2008 Earnings Call Transcript
on Nov 24, 2008about OMRI
Salix Pharmaceuticals Ltd. Company Info
Board of Directors
Mr. John F. Chappell
Chairman
Ms. Carolyn J. Logan
Mr. Thomas W. D' Alonzo
Mr. Richard A. Franco Sr.
Mr. William Harral III
Mr. Wiiliam P. Keane
Dr. Mark A. Sirgo Pharm.D.
Contact Information
1700 Perimeter Park Drive
Morrisville, NC
919 862-1000
NAICS Code
Pharmaceutical Preparation Manufacturing: 325412
